Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 54, No. 4, 2011
Issue release date: June 2011
Section title: Short Communication
Intervirology 2011;54:229–232

Interferon Alone or Combined with Ribavirin for Acute Prolonged Infection with Hepatitis C Virus in Chimpanzees

Tomoguri T.a · Katayama K.b · Tanaka J.b · Yugi H.d · Mizui M.c · Miyakawa Y.e · Yoshizawa H.b
aSanwa Kagaku Kenkyusho Co., Ltd., Kumamoto, bDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical Sciences, Hiroshima University, and cJapanese Red Cross Hiroshima Blood Center, Hiroshima, dDivision of Nucleic Acid Amplification Test (NAT), Japanese Red Cross Tokyo Blood Center, and eMiyakawa Memorial Research Foundation, Tokyo, Japan
email Corresponding Author

Junko Tanaka, PhD

Department of Epidemiology, Infectious Disease Control and Prevention

Graduate School of Biomedical Sciences, Hiroshima University

Kasumi 1-2-3, Minami-Ku, Hiroshima 734-8551 (Japan)

Tel. +81 82 257 5161, Fax +81 82 257 5164, E-Mail jun-tanaka@hiroshima-u.ac.jp

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Infection with hepatitis C virus (HCV) persisted for longer than 29 weeks in 2 chimpanzees after they had been inoculated with it experimentally. One of them (C-210) received short-term subcutaneous interferon-α (IFN-α) 6 million units (MU) daily for 7 days at week 29. He cleared HCV RNA from the serum and remained negative for it during 25 weeks after the withdrawal of IFN. The other (C-224) did not respond to 2 courses of a short-term IFN monotherapy at weeks 20 and 23. Twelve weeks thereafter, he received IFN-α 3 MU daily for 2 weeks and then 3 times a week for 14 weeks combined with oral ribavirin 600 mg daily during 16 weeks. HCV RNA disappeared from the serum and stayed negative until the last follow-up 24 weeks after the completion of combination therapy.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Short Communication

Received: May 03, 2010
Accepted: September 20, 2010
Published online: January 14, 2011
Issue release date: June 2011

Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: http://www.karger.com/INT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.